<DOC>
	<DOCNO>NCT00872625</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Giving radiation therapy high dos shorter period time may kill tumor cell few side effect . Drugs use chemotherapy , docetaxel , epirubicin , cyclophosphamide , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose radiation therapy give together docetaxel follow standard therapy treat woman breast cancer .</brief_summary>
	<brief_title>Radiation Therapy Docetaxel Followed Standard Therapy Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate tolerance concurrent neoadjuvant docetaxel cyberknife hypofractionated radiotherapy follow standard treatment woman breast cancer order find maximum-tolerated dose radiotherapy . Secondary - Evaluate efficacy combination chemoradiotherapy . - Evaluate breast-conserving surgery . - Evaluate quality life . OUTLINE : This dose-escalation study cyberknife hypofractionated radiotherapy . Patients receive neoadjuvant docetaxel IV day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Beginning first second course neoadjuvant chemotherapy , patient undergo hypofractionated radiotherapy . Patients receive standard chemotherapy comprise epirubicin hydrochloride IV , cyclophosphamide IV , fluorouracil IV day 1 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients undergo surgery 4-8 week last course chemotherapy , undergo standard radiotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis breast cancer Unifocal disease Nonmetastatic disease Not candidate breastconserving surgery No superficial breast cancer ( define distance tumor skin â‰¤ 1 cm ) Undergone MRI breast define macroscopic tumor volume Undergone scanning breast mark location radiotherapy PATIENT CHARACTERISTICS : WHO performance status 02 Not pregnant nursing Fertile patient must use effective contraception 6 month completion study treatment No counterindications surgery , standard neoadjuvant chemotherapy , insertion implantable venous device No patient clinical follow impossible psychological , familial , social , geographical reason No patient deprive liberty trusteeship PRIOR CONCURRENT THERAPY : No prior ipsilateral breast irradiation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>